FYCOMPA perampanel (as hemisesquihydrate) 2 mg/4 mL oral suspension Australia - English - Department of Health (Therapeutic Goods Administration)

fycompa perampanel (as hemisesquihydrate) 2 mg/4 ml oral suspension

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 0.52 mg/ml (equivalent: perampanel, qty 0.5 mg/ml) - oral liquid, suspension - excipient ingredients: poloxamer; sodium benzoate; sorbitol solution (70 per cent) (crystallising); citric acid; polysorbate 65; methylcellulose; benzoic acid; sorbic acid; sulfuric acid; purified water; dimeticone 500; silicon dioxide; peg-40 stearate; microcrystalline cellulose; carmellose sodium - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Fycompa 2 mg film-coated tablets European Union - English - myHealthbox

fycompa 2 mg film-coated tablets

eisai europe limited - perampanel - film-coated tablet - 2 mg - epilepsies, partial - antiepileptics, other antiepileptics - indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

Fycompa 4 mg film-coated tablets European Union - English - myHealthbox

fycompa 4 mg film-coated tablets

eisai europe limited - perampanel - film-coated tablets - 4 mg - epilepsies, partial - antiepileptics, other antiepileptics - indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

Fycompa 6 mg film-coated tablets European Union - English - myHealthbox

fycompa 6 mg film-coated tablets

eisai europe limited - perampanel - film-coated tablet - 6 mg - epilepsies, partial - antiepileptics, other antiepileptics - indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older